Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 vs Topotecan in Recurrent SCLC
NCT01803269Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Jan 2013
- Primary completion
- Mar 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CRLX101 in small cell lung cancer (SCLC) (3 arms), sponsored by University of Chicago. Primary endpoint: Progression-free Survival at 12 months. Started Jan 2013; status: terminated.
02
Drugs
CRLX101
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01803269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803269.